Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.

Abstract: Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions.

Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.

Abstract: The present invention relates to compositions and methods for immunomodulation which are effective for increasing conception rate in cows.

Abstract: The present invention provides a combination epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia, wherein the epigenetic factor is selected from the group consisting of histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) I inhibitors, hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibitors and ATRA (All Trans-retinoic acid). Accordingly, the invention provides a pharmaceutical composition comprising a CD33 targeting compound and at least one epigenetic factor and an epigenetic factor for use in the amelioration and/or treatment of a myeloid leukemia, wherein the epigenetic factor increases the responsiveness of a patient to a CD33 targeting compound.

Abstract: The present invention relates to a new anti-BARF1 monoclonal antibody.

Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

Abstract: Methods for the treatment of cardiac hypertrophy are described. Additionally, the presently disclosed subject matter relates to the use of small molecule compounds for the inhibition of Human antigen R (HuR)-mRNA interaction, and more particularly for the reduction of nuclear factor of activated T cells (NFAT) transcriptional activity. Novel methods of screening for small molecule compounds for inhibition of RNA binding proteins interaction with their target RNA (such as HuR-mRNA interactions) or for inhibition of DNA binding proteins to their target DNA are also described.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Abstract: Various embodiments of bulking or cushioning agents or material and related medical devices and methods are disclosed. For example, a method of performing a medical procedure in a tract of a body may include injecting a material in a liquid phase proximate a target site between a first tissue layer and a second tissue layer, allowing the material to transition from the liquid phase to the gel phase in response to a raise in temperature of the material to approximately at or above the predetermined temperature, and performing a surgical procedure on the target site. The material may have the liquid phase at temperatures below a predetermined temperature and a gel phase at temperature approximately at or above the predetermined temperature.

Abstract: The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R3 and R4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.

Abstract: Hydrogels and hybrid hydrogels, methods of making the hydrogels/hybrid hydrogels, and methods of using the hydrogels/hybrid hydrogels. The hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties). The hybrid hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties) and poly(ester amide) moieties. The poly(ester amide) moieties can have one or more arginine moieties. The hydrogels/hybrid hydrogels can be used, for example, in consumer products and as cargo carrier materials (e.g., as therapeutic agent carriers).

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R1—H which comprises a first functional moiety of formula F1 to a second functional moiety of formula F2 wherein X, X?, Y, R1, F1 and F2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.

Abstract: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.

Abstract: The present invention relates to compositions and methods for reducing the risk and/or extent of radiocontrast-induced nephropathy (“RIN”) for kidney-imaging procedures that employ a radiocontrast medium. It is based, at least in part, on the discovery that, in a renal tubular cell line, radiocontrast induced inflammatory upregulation and cell injury could be reduced by calcineurin inhibitors FK506 and cyclosporine.

Abstract: The disclosure relates in some aspects to imaging agents, and in particular, imaging agents for sensing of calcium signaling. According to some embodiments of the disclosure, contrast agents for magnetic resonance imaging and related technologies are provided, and methods of making and using the contrast agents.

Abstract: The present disclosure relates to methods of administering [18F]-FACBC. The present disclosure also relates to use of [18F]-FACBC in methods for imaging, diagnosing and monitoring metastasis or recurrence of cancer.

Abstract: A down-light fixture including both white-light-emitting diodes (LEDs) and antimicrobial ultraviolet (UV-C) LEDs. The white LEDs are arranged in the fixture so as to illuminate surfaces, e.g., items in a room of a building, when actuated. The UV-C LEDs also are arranged in the fixture so as to disinfect or sterilize the surfaces/items in the same room. The illumination LEDs and the disinfection LEDs are independently switchable “on” and “off,” such that a user can controllably illuminate surfaces and/or objects, or disinfect surfaces and/or objects, or both illuminate and disinfect.

Abstract: UV hard-surface disinfection system that is able to disinfect the hard surfaces in a room, while minimizing missed areas due to shadows by providing multiple UV light towers that can be placed in several areas of a room such that shadowed areas are eliminated and that can be transported by a cart that is low to the ground such that the towers may be loaded and unloaded easily by a single operator. The system is able to be controlled remotely, such that during activation of the system, no operator is present, and to automatically cut power to all towers in the event that a person enters the room.

Abstract: A conveyor belt sanitization apparatus and method are provided for sanitizing a conveyor belt of the species commonly found at grocery stores and supermarkets using ultraviolet (UV) light. One or more UV light bulbs in the apparatus may be positioned to effectively sanitize a conveyor belt.

Abstract: A system and methods for sterilizing or disinfecting articles, particularly the hollow internal areas of medical instruments are disclosed. The system includes a plasma generator having an electrode, a shield, and a dielectric gap between the electrode and the shield. A source of electrical power is connected to the plasma generator for applying an electron energy density between the electrode and the shield. A source of gas comprising water vapor, oxygen and nitrogen provides a flow of gas between the electrode and the shield, to form a plasma containing acidic and/or oxidizing species. In the exemplary system, the temperature at the shield's surface is <150° C. when the electron energy density is >0.05 eV/molecule of the gas. Also disclosed is a method for disinfecting an article contaminated with a bio-film or spores, by exposing the contaminated article to the plasma for an exposure time sufficient to achieve at least 2-log10 reduction in colony forming units.

Abstract: Systems and methods for securely delivering, transferring ownership, storing, accessing and receiving or returning an item from another are disclosed herein. In one embodiment, a system and method are provided to securely receive a variety of different sizes and types of packages at one or more locations, including but not limited to on or adjacent a recipient's property. In another embodiment, the system and method allow a user to receive, store and/or return an item without exposing the item to loss, damage, spoilage or other events that would impair the value of the items. Methods of utilizing the systems described herein are also disclosed.

Abstract: Disclosed are an aroma diffusion module and an aroma diffusion container including the same. The aroma diffusion container according to an embodiment of the present invention includes a container body; an opening and closing unit coupled to the upper end of the container body; and an aroma diffusion module mounted in the container body, in which the aroma diffusion module includes a porous module body; a first hollow formed at one side of the module body; and a second hollow formed inside the module body, a porous aroma diffusion medium is accommodated in the first hollow, and the second hollow allows external air to be introduced into the container body through a slit of a membrane member unit.

Abstract: A method and apparatus for vapor dispensing apparatus is described. The vapor dispensing apparatus includes: a housing defining a chamber having an inner contact surface, wherein the housing further comprises an aperture providing fluid communication between the chamber and an external environment; an evaporable material receptacle movably disposed within the chamber such that a dispensing portion of the receptacle is disposed in contact with at least a portion of the surface; and a motor coupled to the apparatus, configured to move the receptacle.

Abstract: A fluid dispensing method, the method comprising steps of: providing a system comprising a reservoir, a micro-fluidic thermal inkjet print head in fluid communication with the reservoir, a controller and a power source in electrical communication with the controller and the print head, the reservoir containing a fluid, the micro-fluidic thermal inkjet print head comprising nozzles; heating the fluid in the microfluidic device to a temperature of about 40 C to 75 C in less than about 1000 ms; activating the print head to fire the nozzles about 200 fires/nozzle at a first frequency; subsequent to step c, activating the print head to fire the nozzles at a second frequency, the second frequency substantially less than the first frequency; and subsequent to step d, activating the print head to fire the nozzles at a third frequency substantially greater than the first frequency.

Abstract: The present invention relates to an apparatus capable of purifying air and maintaining freshness inside a refrigerator while minimizing deformation of the structure of an existing refrigerator, and a method for controlling the same. The apparatus for air purification and freshness maintenance according to the present invention is formed separately from a storage space (12) of a refrigerator (10) and is installed on a cooling passage (14) which communicates with the storage space (12) through an inlet (13) and an outlet (15), wherein a photocatalyst filter (30) is installed in the vicinity of the outlet (15) within the cooling passage (14), and a plurality of cells (32) forming an air vent are formed in the photocatalyst filter (30) in the same direction as the air flow direction within the cooling passage (14), in which a UV LED (41) for radiating ultraviolet rays toward the cells (32) of the photocatalyst filter (30) is installed.

Abstract: A built-in apparatus and method for treating air including a housing with an air inlet and an air outlet. An air mover positioned near the air outlet is configured to draw the air through the air inlet. The housing encloses an air treatment zone, such as including an oxidizing zone, and an ozone removal zone positioned downstream of the air treatment zone and oxidizing zone. The air treatment zone includes UV light and/or ozone that partially oxidizes the chemical contaminants in the air treatment zone. A catalyst in the oxidizing zone oxidizes elements within the air treatment zone. The ozone removal zone includes a second, different catalyst material. A UV bulb that may or may not generate ozone is positioned within or downstream of the first and/or second catalyst materials to assist catalyst oxidation and/or self-clean the apparatus.

Abstract: A built-in apparatus and method for treating air including a housing with an air inlet and an air outlet. An air mover positioned near the air outlet is configured to draw the air through the air inlet. The housing encloses an air treatment zone, such as including an oxidizing zone, and an ozone removal zone positioned downstream of the air treatment zone and oxidizing zone. The air treatment zone includes UV light and/or ozone that partially oxidizes the chemical contaminants in the air treatment zone. A catalyst in the oxidizing zone oxidizes elements within the air treatment zone. The ozone removal zone includes a second, different catalyst material. A UV bulb that may or may not generate ozone is positioned within or downstream of the first and/or second catalyst materials to assist catalyst oxidation and/or self-clean the apparatus.

Abstract: In one aspect, the present invention includes a haemostat composition that has been washed with an alkali solution to reduce the presence of endotoxins, and which is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

Abstract: Cosmetic threads for reducing wrinkle size include at least one synthetic collagen fiber that wells after placement under the skin.

Abstract: Disclosed are an implantable medical device, a preparation method thereof and an implantable medical device preform for the preparation of the implantable medical device. The implantable medical device comprises a metal basal body (21) and a polymer film layer (22) covering the surface of the metal basal body (21) and preventing endothelium growth and covering, and also comprises a transitional body (23), which is located between the metal basal body (21) and the polymer film layer (22) and covers at least part of the surface of the metal basal body (21), wherein the transitional body (23) is connected to the polymer film layer (22) and the metal basal body (21). By arranging the transitional body (23) to be connected to the polymer film layer (22) and the metal basal body (21), the polymer film layer (22) will not easily fall off when being implanted into a human body.

Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.

Abstract: A method includes covering or contacting a portion of a parathyroid of a subject with a shield including extraembryonic tissue and/or a parathyroid protective injection. The covering occurs during a neck or reconstructive surgery of the subject.

Abstract: A prosthetic implant with improved properties, suitable for implantation to the human body, comprising a composite comprising a base material and a plurality of additives, wherein the additives are selected from radiolucent additives and/or hyperechoic additives; or wherein the additives are selected to reduce the solvent concentration by between 5%-95%; or wherein the additives are selected to increase the elastic modulus by more than 20%; or wherein the additives are selected for combining these effects.

Abstract: A mixture of polymers with lubricating properties is provided. The polymer can be used to produce a lubricating fluid. They can also be born on a surface or embedded in a porous material. This mixture of polymers comprises (a) a pharmaceutically acceptable bottle-brush polymer comprising a backbone with polymeric pendant chains, and (b) a pharmaceutically acceptable linear polymer. In the lubricating fluid, the bottle-brush polymer and the linear polymer are dissolved together in a pharmaceutically acceptable solvent.

Abstract: A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.

Abstract: A double network hydrogel consists of a first network and a second network, where the first network is, or includes, a first polymer that is formed, at least in part, of —CH2—CH(OH)— units, and the second network is, or includes, a second polymer that is formed, at least in part, of carboxyl (COOH)-containing units or salts thereof, sulfonyl (SO3H)-containing units or salts thereof, and at least one of hydroxyl (OH)-containing units or amino (NH2)-containing units, where the hydrogel may be used as a cartilage replacement.

Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat.

Abstract: Drug delivery devices are provided in which much of a drug payload within the device remains within an area proximal to a wall of the device through which the drug must pass for release of the drug from the device into a patient. In one case, the device may include a drug reservoir portion which has a drug reservoir lumen bounded by a reservoir wall having an inner surface; a drug located in the drug reservoir lumen; and a core region which does not comprise the drug, wherein the drug is disposed between the inner surface of the reservoir wall and the core region. The device may be elastically deformable between a first shape suited for insertion through a lumen into a body cavity of the patient and a second shape suited to retain the device within the body cavity.

Abstract: Object of the present invention is to provide a safe sol for submucosal local injection which gels and creates a mucosal elevation having a high retention rate of mucosal elevation height when locally injected into a digestive submucosa. Provided is a sol for submucosal local injection containing from 0.2 mass % to 1.2 mass % of a collagen, water, a buffer, and from 200 mM to 420 mM sodium chloride.

Abstract: Implantable medical devices are provided. In one embodiment, a device includes a body having an external surface defining an outer profile of the device. The body includes a porous matrix including a series of interconnected macropores defined by a plurality of interconnected struts each including a hollow interior. A filler material substantially fills at least a portion of the series of interconnected macropores. The external surface of the body includes a plurality of openings communicating with the hollow interior of at least a portion of the plurality of interconnected struts. In a further aspect of this embodiment, the external surface includes exposed areas of the filler material and porous matrix in addition to the exposed openings. In another aspect, the porous matrix is formed from a bioresorbable ceramic and the filler material is a biologically stable polymeric material. Still, other aspects related to this and other embodiments are also disclosed.

Abstract: A microneedle or microneedle device includes a microneedle body extending from a base to a penetrating tip formed from a silk fibroin based material, which is easy to fabricate and highly biocompatible. The microneedle device can include one or more microneedles mounted to a substrate. The silk fibroin can include active agents to be transported into or across biological barriers such as skin, tissue and cell membranes. The silk fibroin microneedles can be fully or partially biodegradable and/or bioerodible. The silk fibroin is highly stable, affords room temperature storage and is implantable. The silk fibroin structure can be modulated to control the rate of active agent delivery.

Abstract: An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed.

Abstract: A chest drainage system including a collection device configured to receive fluid from the pleural cavity of a patient. A sensor is included to detect a pressure differential in the fluid. A display is configured to display a trend in occurrences of changes in pressure of the fluid over time in predetermined time increments based on a number of detections of pressure differentials that exceed a predetermined pressure differential during each of the predetermined time increments. The trend is correlative to the percentage of time that the patient is deemed to have an air leak in the pleural cavity in the predetermined time increments. The trend is derived from a ratio of the quantity of respiratory cycles of the patient for which the predetermined pressure differential is detected (QRCleak) in the predetermined time increments to the total quantity of respiratory cycles of the patient in respective predetermined time increments (QRCtotal).

Abstract: Medical waste collection manifolds that that may connect to a vacuum system to create suction, such that liquid, semi-solid, or solid biological or medical waste may be collected are provided. The manifold may be configured to collect hazardous waste in a manner to ensure proper containment.

Abstract: Systems and methods for delivery of fluid to a wound therapy dressing. In exemplary embodiments, a pressure sensor measures the pressure at the wound therapy dressing and restricts fluid flow to the wound therapy dressing when a predetermined pressure is achieve.